Therapeutic Asset Ratings

8,400 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Benadryl Anemia, Sickle Cell	Columbia University	P1/2	CCC (55)
Carboplatin Soft Tissue Sarcoma	OHSU Knight Cancer Institute	P1/2	CCC (55)
cd22 car-transduced t cells Childhood Acute Lymphoblastic Leukemia	Sumithira Vasu	P1/2	CCC (55)
Cetuximab Cervical Squamous Cell Carcinoma	Hummingbird Bioscience	P1/2	CCC (55)
Chimeric Antigen Receptor Modified T Cells Infusion Advanced Hepatocellular Carcinoma	National Cancer Institute (NCI)	P1/2	CCC (55)
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE T Cell Lymphoma	Won Seog Kim	P1/2	CCC (55)
CIS-DIAMMINEDICHLOROPLATINUM II Chondrosarcoma	Eli Lilly and Company	P1/2	CCC (55)
Cobimetinib Breast Carcinoma	OHSU Knight Cancer Institute	P1/2	CCC (55)
com701 Ovarian Cancer	Compugen Ltd	P1/2	CCC (55)
Cyclophosphamide Solid Cancer	Beijing GoBroad Hospital	P1/2	CCC (55)
DARATUMUMAB Solid Tumors	Hellenic Society of Hematology	P1/2	CCC (55)
DEXAMETHASONE Nasopharyngeal Carcinoma	Takeda	P1/2	CCC (55)
Eloxatin Chemotherapy-induced Peripheral Neuropathy	Fox Chase Cancer Center	P1/2	CCC (55)
Eloxatin Head and Neck Cancer	Taiho Pharmaceutical Co., Ltd.	P1/2	CCC (55)
Evomela Neoplasm	Jonsson Comprehensive Cancer Center	P1/2	CCC (55)
Fludarabine B Cell Malignancies	University Hospital, Basel, Switzerland	P1/2	CCC (55)
Fludarabine Brain Cancer	Essen Biotech	P1/2	CCC (55)
Fludarabine Ewing Sarcoma	Essen Biotech	P1/2	CCC (55)
Fludarabine Fallopian Tube Carcinoma	Beijing Biotech	P1/2	CCC (55)
Fruquintinib Hormone Receptor-Positive Breast Cancer	Immunitas Therapeutics	P1/2	CCC (55)
Glucagon Metabolic Dysfunction-Associated Steatotic Liver Disease	Columbia University	P1/2	CCC (55)
gsk1120212 Metastatic Malignant Neoplasm	OHSU Knight Cancer Institute	P1/2	CCC (55)
Hbi-002 Sickle Cell Disease	Hillhurst Biopharmaceuticals, Inc.	P1/2	CCC (55)
IMMUNOGLOBULIN G1, ANTI-(HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYPE VEGFR-2 EXTRACELLULAR DOMAIN) (HUMAN MONOCLONAL IMC-1121B .GAMMA.-CHAIN), DISULPHIDE WITH HUMAN MONOCLONAL IMC-1121B .KAPPA.-CHAIN, DIMER Gastric Adenocarcinoma	Astellas Pharma Global Development, Inc.	P1/2	CCC (55)
IMMUNOTHERAPIC BIFUNCTIONAL FUSION PROTEIN COMPRISED OF A FULLY HUMAN IGG1 MONOCLONAL ANTIBODY (AVELUMAB) AGAINST HUMAN PROGRAMMED DEATH-LIGAND 1 (PD-L1) FUSED TO THE SOLUBLE EXTRACELLULAR DOMAIN OF TRANSFORMING GROWTH FACTOR-.BETA. (TGF-.BETA.) RECEPTOR II, WHICH ACTS AS A TGF-.BETA. TRAP Reproductive System Cancer	National Cancer Institute (NCI)	P1/2	CCC (55)

Showing 226 to 250 of 8,400 assets

PreviousPage 10 of 336Next